Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yukitoshi Takahashi is active.

Publication


Featured researches published by Yukitoshi Takahashi.


Pharmacogenomics | 2008

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis.

Nahoko Kaniwa; Yoshiro Saito; Michiko Aihara; Kayoko Matsunaga; Masahiro Tohkin; Kouichi Kurose; Jun-ichi Sawada; Hirokazu Furuya; Yukitoshi Takahashi; Masaaki Muramatsu; Shigeru Kinoshita; Masamichi Abe; Hiroko Ikeda; Mariko Kashiwagi; Yixuan Song; Mayumi Ueta; Chie Sotozono; Zenro Ikezawa; Ryuichi Hasegawa

INTRODUCTION Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening severe cutaneous adverse reactions. Recently, strong associations of HLA-B*1502 and HLA-B*5801 with carbamazepine- and allopurinol-induced severe cutaneous adverse reactions were found in Han Chinese patients, respectively, but ethnic differences in the associations have been reported. The objective of this study is to clarify the involvement of HLA-B*1502 and HLA-B*5801 in Japanese SJS/TEN patients. METHODS HLA-B genotyping was performed on 58 Japanese SJS/TEN patients between July 2006 and April 2008 from multicenters in Japan. RESULTS There were no HLA-B*1502 carriers among 58 SJS/TEN patients. This patient group included seven carbamazepine-related and 11 aromatic anti-epileptic agent-related SJS/TEN patients. In addition, there were five HLA-B*5801 carriers, which included four allopurinol-related SJS/TEN patients. CONCLUSION While HLA-B*1502 is unlikely to be associated with carbamazepine-related or aromatic anti-epileptic agent-related SJS/TEN, HLA-B*5801 was significantly associated with allopurinol-related SJS/TEN in Japanese.


Epilepsia | 2010

HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients

Nahoko Kaniwa; Yoshiro Saito; Michiko Aihara; Kayoko Matsunaga; Masahiro Tohkin; Kouichi Kurose; Hirokazu Furuya; Yukitoshi Takahashi; Masaaki Muramatsu; Shigeru Kinoshita; Masamichi Abe; Hiroko Ikeda; Mariko Kashiwagi; Yixuan Song; Mayumi Ueta; Chie Sotozono; Zenro Ikezawa; Ryuichi Hasegawa

Stevens‐Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life‐threatening severe cutaneous adverse reactions. Recently, strong associations of HLA‐B*1502 with carbamazepine‐induced SJS/TEN have been found in Han Chinese patients. These associations have been confirmed in several Asian populations, excluding Japanese. SJS patients carrying HLA‐B*1508, HLA‐B*1511, or HLA‐B*1521, which are members of the HLA‐B75 type along with HLA‐B*1502, were detected in studies in India and Thailand. In the current study, we genotyped the HLA‐B locus from 14 Japanese typical and atypical SJS/TEN patients in whom carbamazepine was considered to be involved in the onset of adverse reactions. Although there were no HLA‐B*1502 carriers, four patients had HLA‐B*1511. Our data suggest that HLA‐B*1511, a member of HLA‐B75, is a risk factor for carbamazepine‐induced SJS/TEN in Japanese.


JAMA | 2014

Genetic Variants Associated With Phenytoin-Related Severe Cutaneous Adverse Reactions

Wen-Hung Chung; Wan-Chun Chang; Yun-Shien Lee; Ying-Ying Wu; Chih-Hsun Yang; Hsin-Chun Ho; Ming-Jing Chen; Jing-Yi Lin; Rosaline Chung-Yee Hui; Ji-Chen Ho; Wei-Ming Wu; Ting-Jui Chen; Tony Wu; Yih-Ru Wu; Mo-Song Hsih; Po-Hsun Tu; Chen-Nen Chang; Chien-Ning Hsu; Tsu-Lan Wu; Siew-Eng Choon; Chao-Kai Hsu; Der-Yuan Chen; Chin-San Liu; Ching-Yuang Lin; Nahoko Kaniwa; Yoshiro Saito; Yukitoshi Takahashi; Ryosuke Nakamura; Hiroaki Azukizawa; Yongyong Shi

IMPORTANCE The antiepileptic drug phenytoin can cause cutaneous adverse reactions, ranging from maculopapular exanthema to severe cutaneous adverse reactions, which include drug reactions with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis. The pharmacogenomic basis of phenytoin-related severe cutaneous adverse reactions remains unknown. OBJECTIVE To investigate the genetic factors associated with phenytoin-related severe cutaneous adverse reactions. DESIGN, SETTING, AND PARTICIPANTS Case-control study conducted in 2002-2014 among 105 cases with phenytoin-related severe cutaneous adverse reactions (n=61 Stevens-Johnson syndrome/toxic epidermal necrolysis and n=44 drug reactions with eosinophilia and systemic symptoms), 78 cases with maculopapular exanthema, 130 phenytoin-tolerant control participants, and 3655 population controls from Taiwan, Japan, and Malaysia. A genome-wide association study (GWAS), direct sequencing of the associated loci, and replication analysis were conducted using the samples from Taiwan. The initial GWAS included samples of 60 cases with phenytoin-related severe cutaneous adverse reactions and 412 population controls from Taiwan. The results were validated in (1) 30 cases with severe cutaneous adverse reactions and 130 phenytoin-tolerant controls from Taiwan, (2) 9 patients with Stevens-Johnson syndrome/toxic epidermal necrolysis and 2869 population controls from Japan, and (3) 6 cases and 374 population controls from Malaysia. MAIN OUTCOMES AND MEASURES Specific genetic factors associated with phenytoin-related severe cutaneous adverse reactions. RESULTS The GWAS discovered a cluster of 16 single-nucleotide polymorphisms in CYP2C genes at 10q23.33 that reached genome-wide significance. Direct sequencing of CYP2C identified missense variant rs1057910 (CYP2C9*3) that showed significant association with phenytoin-related severe cutaneous adverse reactions (odds ratio, 12; 95% CI, 6.6-20; P=1.1 × 10(-17)). The statistically significant association between CYP2C9*3 and phenytoin-related severe cutaneous adverse reactions was observed in additional samples from Taiwan, Japan, and Malaysia. A meta-analysis using the data from the 3 populations showed an overall odds ratio of 11 (95% CI, 6.2-18; z=8.58; P < .00001) for CYP2C9*3 association with phenytoin-related severe cutaneous adverse reactions. Delayed clearance of plasma phenytoin was detected in patients with severe cutaneous adverse reactions, especially CYP2C9*3 carriers, providing a functional link of the associated variants to the disease. CONCLUSIONS AND RELEVANCE This study identified CYP2C variants, including CYP2C9*3, known to reduce drug clearance, as important genetic factors associated with phenytoin-related severe cutaneous adverse reactions.


Neurology | 2004

Germline and mosaic mutations of FLN1 in men with periventricular heterotopia

Renzo Guerrini; Davide Mei; Sanjay M. Sisodiya; Federico Sicca; Brian Harding; Yukitoshi Takahashi; Thomas Dorn; A. Yoshida; Josep M. Campistol; G. Krämer; Francesca Moro; William B. Dobyns; Elena Parrini

Objective: To describe the phenotypic spectrum and genetics of periventricular nodular heterotopia (PNH) caused by FLN1 mutations in four men. Background: X-linked PNH caused by FLN1 mutations (MIM #300049) implies prenatal or early postnatal lethality in boys and 50% recurrence risk in daughters of affected women. Methods: Clinical examination, cognitive testing, MRI, and mutation analysis (denaturing high-performance liquid chromatography and direct sequencing) on blood lymphocytes and single hair roots were performed for nine affected individuals, including three men. Neuropathologic study of the brain was performed for an affected boy. Results: In two families, missense mutations were transmitted from mother to son (Met102Val) and from father to daughter (Ser149Phe), causing mild phenotypes in both genders, including unilateral PNH. In a third family, a man was mosaic for an A>G substitution (intron 11 acceptor splice site) on leukocyte DNA and hair roots (mutant = 42% and 69%). Single hair root analysis confirmed that the mutation was not present in all ectodermal derivative cells. A healthy daughter had inherited the X chromosome from her father’s wild-type germinal cell population. In the fourth family, an eight-base deletion (AGGAGGTG, intron 25 donor splice site) led to early deaths of boys. Postmortem study in a newborn boy revealed PNH and cardiovascular, genitourinary, and gut malformations. Conclusions: Periventricular nodular heterotopia caused by FLN1 mutations in men has a wide clinical spectrum and is caused by different genetic mechanisms, including somatic mosaicism. Mutation analysis of FLN1 should support genetic counseling in men with periventricular nodular heterotopia.


Epilepsia | 2010

HLA Class I markers in Japanese patients with carbamazepine‐induced cutaneous adverse reactions

Hiroko Ikeda; Yukitoshi Takahashi; Etsuko Yamazaki; Tateki Fujiwara; Nahoko Kaniwa; Yoshiro Saito; Michiko Aihara; Mariko Kashiwagi; Masaaki Muramatsu

Carbamazepine (CBZ) is frequently used for treating epilepsy, but this drug causes cutaneous adverse drug reactions (cADRs) that may range from mild to severe. It is reported recently that the human leukocyte antigen HLA‐B*1502 is associated with Stevens‐Johnson syndrome (SJS) induced by CBZ in Han Chinese. We examined HLA class I in 15 Japanese patients who fulfilled the diagnostic criteria for CBZ‐induced cADRs (mild in 10 and severe = SJS in 5). HLA‐B*1518, HLA‐B*5901 and HLA‐C*0704 alleles showed higher relative risks (above 10.0) for severe cADRs. The haplotype (HLA‐A*2402‐B*5901‐C*0102) had high relative risk (16.09) for severe cADRs. In patients with severe cADRs, frequencies of HLA‐A*1101, HLA‐A*3303, HLA‐B*1501, HLA‐B*4403, HLA‐B*5101, HLA‐B*5201, HLA‐C*0702, and HLA‐C*1202 alleles are relatively lower than in the Japanese population. These data may suggest that HLA‐B*5901 is one of the candidate markers for CBZ‐induced SJS in Japanese.


Neurology | 2008

Total deletion and a missense mutation of ITPR1 in Japanese SCA15 families

Kenju Hara; Atsushi Shiga; Hiroaki Nozaki; Jun Mitsui; Yukitoshi Takahashi; Hiroshi Ishiguro; H. Yomono; H. Kurisaki; Jun Goto; Takeshi Ikeuchi; Shoji Tsuji; Masatoyo Nishizawa; Osamu Onodera

Background: Spinocerebellar ataxia type 15 (SCA15) is a progressive neurodegenerative disorder characterized by pure cerebellar ataxia, very slow progression, and distinct cerebellar atrophy. The locus for SCA15 was first mapped to 3p24.2-3pter in an Australian family. We have subsequently mapped two Japanese families presenting with ataxia and postural tremor of the head, arm, or trunk to the SCA15 locus. Recently, partial deletions involving both the type 1 inositol 1,4,5-triphosphate receptor (ITPR1) and sulfatase modifying factor 1 (SUMF1) genes have been identified in Australian and British families with SCA15. Methods: We conducted fine haplotype analysis on the region including ITPR1. To identify the deletion, we conducted gene dosage analysis and array-based comparative genomic hybridization (aCGH) analysis. Gene expression analysis was performed using quantitative real-time reverse transcription PCR. Mutational analyses of ITPR1 and SUMF1 were also performed. Results: We have identified a 414-kb deletion including the entire ITPR1 and exon 1 of SUMF1 in patients in family A. The expression levels of ITPR1 and SUMF1 mRNAs of the patient were half those of the normal control. Furthermore, in family B, we have identified a C-to-T substitution at position 8581 of ITPR1, resulting in the amino acid substitution of leucine for proline at codon 1059, which is highly conserved among species. Conclusions: Our results strongly confirm that ITPR1 is the causative gene for SCA15 and suggest that we need to investigate the point mutation in ITPR1 in the patients with autosomal dominant cerebellar ataxia and tremor.


Neurology | 2003

Autoantibodies to NMDA receptor in patients with chronic forms of epilepsia partialis continua

Yukitoshi Takahashi; Hidemaro Mori; Masayoshi Mishina; Masahiko Watanabe; Takeki Fujiwara; Jiro Shimomura; H. Aiba; T. Miyajima; Yoshiaki Saito; A. Nezu; Hiroshi Nishida; Katsumi Imai; N. Sakaguchi; Naomi Kondo

Background: Antibody-mediated and cytotoxic T cell-mediated pathogenicity have been implicated as the autoimmune pathophysiologic mechanisms in Rasmussen’s encephalitis. Methods: The authors investigated autoantibodies against the NMDA glutamate receptor (GluR) ε2 subunit and their epitopes in serum and CSF samples from 15 patients with chronic epilepsia partialis continua (EPC), 17 with West syndrome, 10 with Lennox–Gastaut syndrome, and 11 control subjects. Results: In 15 patients with chronic EPC, we detected NMDA-type GluR ε2 autoantibodies in histologically proven Rasmussen’s encephalitis (3/3 patients), clinical Rasmussen’s encephalitis (6/7 patients), acute encephalitis/encephalopathy (2/3 patients), and nonprogressive EPC (2/2 patients). Serum IgM autoantibodies were found in the early phase of EPC and became negative later in four patients. The autoantibodies were not detected in West syndrome, Lennox–Gastaut syndrome, or controls. Among 10 patients with histologically proven or clinical Rasmussen’s encephalitis, epitope analyses showed that the autoantibodies were predominantly against C-terminal epitopes and rarely against N-terminal epitope, with inconsistency in profile during the courses of disease. Epitope recognition spectrum of autoantibodies was broader in CSF than in serum, and the serum or CSF profile showed an increase in number of epitopes as disease progressed in some patients. Conclusions: The presence of autoantibodies against NMDA GluR ε2 suggests autoimmune pathologic mechanisms but is not a hallmark of Rasmussen’s encephalitis. Patients with Rasmussen’s encephalitis may have autoantibodies against several neural molecules, and these autoantibodies may be produced in the CNS after cytotoxic T cell-mediated neuronal damage.


Epilepsia | 2005

Autoantibodies and Cell-mediated Autoimmunity to NMDA-type GluRε2 in Patients with Rasmussen's Encephalitis and Chronic Progressive Epilepsia Partialis Continua

Yukitoshi Takahashi; Hisashi Mori; Masayoshi Mishina; Masahiko Watanabe; Naomi Kondo; Jiro Shimomura; Yuko Kubota; Kazumi Matsuda; Katsuyuki Fukushima; Naohide Shiroma; Noriyuki Akasaka; Hiroshi Nishida; Atsushi Imamura; Hiroo Watanabe; Nobuyoshi Sugiyama; Makoto Ikezawa; Tateki Fujiwara

Summary:  Purpose: To evaluate antibody‐mediated and cytotoxic T cell–mediated pathogenicity that has been implicated as the autoimmune pathophysiological mechanism in Rasmussens encephalitis.


Acta Neurologica Scandinavica | 2010

Acute encephalitis with refractory, repetitive partial seizures (AERRPS): a peculiar form of childhood encephalitis

Hiroshi Sakuma; Y. Awaya; M. Shiomi; H. Yamanouchi; Yukitoshi Takahashi; Yoshiaki Saito; Kenji Sugai; M. Sasaki

Sakuma H, Awaya Y, Shiomi M, Yamanouchi H, Takahashi Y, Saito Y, Sugai K, Sasaki M. Acute encephalitis with refractory, repetitive partial seizures (AERRPS): a peculiar form of childhood encephalitis. 
Acta Neurol Scand: 2010: 121: 251–256.
© 2009 The Authors Journal compilation


Neurology | 2002

Heterogeneity of presenile dementia with bone cysts (Nasu–Hakola disease): Three genetic forms

Takayuki Kondo; K. Takahashi; N. Kohara; Yukitoshi Takahashi; S. Hayashi; Hitoshi Takahashi; H. Matsuo; M. Yamazaki; K. Inoue; K. Miyamoto; T. Yamamura

Abstract—Nasu–Hakola disease (NHD) is an autosomal recessive disorder characterized by presenile dementia and bone cysts. Finnish patients revealed a large deletion in DAP12 gene encoding a key element for transducing activation signal. The authors examined six Japanese cases for DAP12 alleles. Five of the six had loss-of-function mutation, either a single-base deletion or a novel point mutation. The single patient without mutation normally expressed DAP12 protein. Japanese NHD has at least three genetic forms regarding DAP12.

Collaboration


Dive into the Yukitoshi Takahashi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rumiko Takayama

Sapporo Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michiko Aihara

Yokohama City University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Yukiko Mogami

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge